Inhibikase Therapeutics, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Subsequent Events - (Additional Information) (Details) - USD ($)		1 Months Ended
	Feb. 01, 2024	Mar. 31, 2026	Feb. 28, 2026
Wainwright Agreement [Member] \| H.C. Wainwright & Co., LLC [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Sale of Stock, Consideration Received Per Transaction	$ 5,659,255
Subsequent Event
Subsequent Event [Line Items]
Total potential milestone payments		$ 48,200,000
Increasing the total contracted amount		73,700,000
Contigent payment of performance milestones		$ 7,500,000
Subsequent Event \| Sales Agreement [Member]
Subsequent Event [Line Items]
Number of common stock sold			1,904,762
Sale of Stock, Consideration Received Per Transaction			$ 3,000,000